Company / SG&A Expense
IRONWOOD PHARMACEUTICALS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$82.3M
FY2025
5-year range
$82.3M / $158.3M
FY2021-FY2025
Trend
-29.1%
vs FY2024
Sector context
#125 of 213
Health Care
What the data says
At $82M, IRONWOOD PHARMACEUTICALS INC's sg&a expense ranks #89 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $82M in FY2025 to $231M in FY2017.
Based on SEC 10-K filings.
$82M in FY2025 with a 5-year CAGR of -17.8%.
Improved from $158M to $82M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -16.2%
- 5-Year CAGR
- -17.8%
- 10-Year CAGR
- -
Sector benchmark
#89 of 213 in Health CareTop 41% of 213This company $82.3M Sector average $722.3M
▼
-88.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -17.8%, indicating a declining trend.
- In FY2025, sg&a expense decreased 29.1% year-over-year.
- Ranks #125 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -2.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $82.3M | -29.1% |
| FY2024 | $116.0M | -26.7% |
| FY2023 | $158.3M | +13.1% |
| FY2022 | $140.0M | +26.0% |
| FY2021 | $111.1M | -49.4% |
| FY2020 | $219.7M | +27.4% |
| FY2019 | $172.4M | -0.5% |
| FY2018 | $173.3M | -25.0% |
| FY2017 | $231.2M | +33.4% |
| FY2016 | $173.3M | +38.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026